Cargando…
Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects
PURPOSE: Treatment for chronic lymphocytic leukemia (CLL) has changed dramatically with the approval of novel agents. Information regarding how patients and oncologists make trade-offs across attributes of novel therapies is limited. The purpose of this study was to understand how variations in attr...
Autores principales: | Le, Hannah, Ryan, Kellie, Wahlstrom, Svea K, Maculaitis, Martine C, Will, Oliver, Mulvihill, Emily, LeBlanc, Thomas W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837542/ https://www.ncbi.nlm.nih.gov/pubmed/33519195 http://dx.doi.org/10.2147/PPA.S289139 |
Ejemplares similares
-
Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best–Worst Scaling
por: Maculaitis, Martine C, et al.
Publicado: (2020) -
Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
por: Beusterien, Kathleen, et al.
Publicado: (2021) -
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023) -
Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment
por: Yong, Candice, et al.
Publicado: (2022) -
A Mobile App to Support Self-Management in Patients with Multiple Myeloma or Chronic Lymphocytic Leukemia: Pilot Randomized Controlled Trial
por: LeBlanc, Matthew R, et al.
Publicado: (2023)